宫颈癌分子靶向药物的研究进展

Advances in molecularly targeted agents for cervical cancer

晚期及复发性宫颈癌预后差,尚缺乏有效的治疗手段。许多研究以宫颈癌形成过程中的各种信号转导环节为靶向,寻找新药物和治疗策略,包括靶向抑制肿瘤血管生成、表皮生长因子、哺乳动物雷帕霉素靶蛋白(mTOR)、环氧合酶-2、组蛋白去乙酰化酶等。虽然还没有任何药物被准予临床应用,但有关贝伐单抗的临床试验结果显示出靶向肿瘤血管生成通路是颇具吸引力的宫颈癌治疗策略。随着宫颈癌成因机制的明了,分子靶向药物的产生及应用将会为宫颈癌的治疗开辟新的途径。

Advanced and recurrent cervical cancer has a poor prognosis and few effective therapeutic options. Many efforts have been made to design new drugs and therapies modulating different signal transduction pathways to treat cervical cancer, inhibiting angiogenesis, targeting epidermal growth factor receptor （EGFR）, mammalian target of rapamycin （mTOR）, cyclooxygenase-2 or histone deacetylases. Although no agent has been approved for use in clinical practice, the promising results of bevacizumab in therapeutic trials for cervical cancer have shown that targeting the VEGF pathway is an attractive therapeutic strategy. As knowledge accumulates on the molecular mechanisms underlying carcinogenesis in the cervix, the anticipated development of molecularly targeted agents may offer a promising perspective for cervical cancer.